An Open-Label Study to Assess the Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Any Interferon Plus Ribavirin in Vietnam
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 12 Aug 2013
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 12 Aug 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 Nov 2012 Planned End Date changed from 1 Mar 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
- 06 Nov 2012 Planned initiation date changed from 1 Oct 2012 to 1 May 2014 as reported by ClinicalTrials.gov record.